ESCRT-mediated membrane remodeling in cancer immune evasion and resistance to immunotherapy: mechanisms, therapeutic vulnerabilities, and translational implications
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.117007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Haian Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng 224000, China; Medical …. Hauptthemen laut MEDLINE: Endosomal Sorting Complexes Required for Transport, Neoplasms, Immunotherapy, Tumor Escape. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 171 Literaturangaben.
Abstract (Originalsprache)
Cancer immunotherapy has improved outcomes in multiple malignancies, yet primary and acquired resistance remain major barriers to durable benefit. In addition to oncogenic signaling and tumor microenvironmental dysregulation, accumulating evidence indicates that membrane remodeling is an underappreciated determinant of tumor immune escape and therapeutic adaptation. As a conserved membrane-remodeling machinery, the endosomal sorting complexes required for transport (ESCRT) regulate plasma membrane repair, nuclear envelope resealing, endosomal sorting, multivesicular body (MVB) formation, and extracellular vesicle release. Through these functions, ESCRT may contribute to resistance to immunotherapy through three interconnected mechanisms: by increasing the lytic threshold and limiting immune effector-mediated membrane damage, by reducing immune visibility through restriction of innate immune sensing and endolysosomal turnover of immune-related surface molecules, and by enhancing the systemic burden of immunosuppressive small extracellular vesicles, particularly programmed death-ligand 1 (PD-L1)-positive vesicles. In this review, we summarize the mechanistic basis of ESCRT-mediated membrane remodeling in tumor immune evasion and discuss its implications for cytotoxic lymphocyte attack, lytic cell death programs, cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling, antigen presentation, and vesicle-mediated immunosuppression. We further highlight potential therapeutic opportunities, informative translational readouts, and key safety constraints relevant to targeting this pathway. Collectively, current evidence supports ESCRT-associated membrane remodeling as a promising but context-dependent axis for improving cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng 224000, China; Medical School of Nantong University, Nantong 226007, China; Nantong Universit…
- Department of Cardiothoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng 224000, China.
- Department of Cardiothoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng 224000, China; Nantong University, Nantong 226007, China. Electronic address: 13770067799@163…
Zitieren
APA
Wang, H., Gu, Y., Liu, J., Tan, H., Li, J., Li, J., Shi, W., & Zhang, Y. (2026). ESCRT-mediated membrane remodeling in cancer immune evasion and resistance to immunotherapy: mechanisms, therapeutic vulnerabilities, and translational implications. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.117007
Vancouver
Wang H, Gu Y, Liu J, Tan H, Li J, Li J, et al. ESCRT-mediated membrane remodeling in cancer immune evasion and resistance to immunotherapy: mechanisms, therapeutic vulnerabilities, and translational implications. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.117007
BibTeX
@article{Wang2026,
author = {Wang, Haian and Gu, Yan and Liu, Jiaqi and Tan, Hui and Li, Jie and Li, Jielong and Shi, Woda and Zhang, Yajun},
title = {ESCRT-mediated membrane remodeling in cancer immune evasion and resistance to immunotherapy: mechanisms, therapeutic vulnerabilities, and translational implications},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.117007}
}
EUVIMED